BusinessAXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South KoreaBy Nasdaq OMXApr 3, 2018, 1:02 PM UTC
BusinessAxim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)By Nasdaq OMXNov 21, 2017, 2:00 PM UTC
BusinessAXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency StudyBy Nasdaq OMXJun 19, 2017, 1:00 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing GumBy Nasdaq OMXJan 18, 2017, 2:01 PM UTC
